How Treatment-Resistant Depression Is Diagnosed: The Two-Failed-Trials Standard, Explained

You tried the first antidepressant. Nothing happened, or maybe something happened for a while and then it stopped. You tried a second one. Same result. Now your doctor is using a term that no one has actually explained to you: treatment-resistant depression.

Here’s what they should have told you from the start.

You’re not “resistant.” Your treatment was.

The word “resistant” sounds like something is wrong with you — like your brain is stubborn, broken, or simply not trying hard enough. That framing is wrong, and it’s worth correcting before we go any further.

Treatment-resistant depression (TRD) is not a character flaw or a biological dead-end. It’s a clinical designation that means a specific thing: the treatments tried so far were not the right ones for your specific brain. Roughly 30% of people diagnosed with major depression don’t respond adequately to standard antidepressants and meet some definition of TRD; under the stricter FDA/EMA criteria applied in the STAR*D trial, that number climbs toward 55% ^[1]. You are not the rare exception. You are, statistically, a substantial share of every psychiatric clinic’s caseload.

What the diagnosis does is open a different clinical pathway — one with access to advanced, targeted treatments that aren’t offered on the standard track. Getting here was not a failure. In many cases, it was necessary.

So what is the “two-failed-trials” standard?

The most widely used clinical definition of TRD, endorsed by both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), is this: failure to respond adequately to at least two different antidepressants, given at the right dose, for the right amount of time, within the same depressive episode ^[1].

That definition sounds simple. It isn’t. Each part of it carries weight.

What makes a trial “adequate”?

This is where the diagnosis gets specific, and where a lot of patients have been misled. An adequate antidepressant trial requires three things to be true at the same time ^[1,2].

1. The right dose. Not the starting dose. Not the “let’s see how you tolerate it” dose. The therapeutic dose — the dose that clinical evidence shows actually works for depression. Many prescribers, especially in primary care, never titrate patients to a full therapeutic dose before calling the medication a failure. Studies consistently document under-dosing as one of the most common reasons depression looks treatment-resistant when it isn’t ^[1,2].

2. Enough time. Antidepressants need a minimum of 6 to 8 weeks at a therapeutic dose before you can fairly judge whether they’re working ^[1]. The biology behind this matters: these medications don’t just tweak brain chemistry overnight. They desensitize serotonin autoreceptors over weeks, upregulate brain-derived neurotrophic factor (BDNF, a protein critical to neuronal resilience), and gradually rebuild neural connections that depression has eroded ^[3]. Stopping at week 3 or 4 because you don’t feel better isn’t a failed trial. It’s an incomplete one.

3. Consistent adherence. Clinical standards define adequate adherence as taking at least 80% of prescribed doses ^[1]. This isn’t a moral judgment — missing doses is common and human — but inconsistent blood levels of an antidepressant can prevent it from reaching its therapeutic potential. Non-adherence rates in major depression run 30–60% and are worth confirming, sometimes with plasma drug levels, before declaring a medication a failure ^[1].

If any one of these three conditions wasn’t met, the trial doesn’t count as a genuine failure. A psychiatrist’s job, before applying the TRD label, is to go back through your entire medication history and verify all three for each drug you’ve tried ^[1].

The honest truth about antidepressants

Here’s what most people are not told when they first receive a prescription for an SSRI.

Antidepressants don’t work for everyone. A rigorous, independent reanalysis of the STAR*D trial — the largest real-world antidepressant study ever conducted, originally funded by the National Institute of Mental Health — found a step-by-step cumulative remission rate that tells a sobering story. Only 25.5% of patients achieved remission on the first medication, declining to 21.3% on the second, 13.2% on the third, and 10.4% on the fourth. The cumulative remission rate after up to four sequential antidepressant trials was 35% — roughly half the figure originally reported by the STAR*D investigators ^[4].

This is not a pessimistic statistic. It’s a clarifying one. If your antidepressant hasn’t worked, you’re not failing medication. Medication has simply not been the complete answer for your brain. That’s actionable information, because it points toward what might actually work.

The monoamine hypothesis — the idea that depression is just a “low serotonin” problem — has been challenged by decades of research. A landmark Lancet Psychiatry review confirmed that while SSRIs do increase serotonin availability in the synapse, the therapeutic effect is far more complex, involving delayed neuroplastic changes that emerge over weeks and don’t occur in everyone ^[3]. For people with TRD, the underlying biological drivers often involve systems that SSRIs and SNRIs don’t adequately address: glutamate signaling, neuroinflammation, HPA axis dysregulation, or mitochondrial dysfunction ^[1].

Could it be “pseudoresistance”?

This is one of the most important questions in TRD diagnosis, and a skilled psychiatrist must ask it before confirming the label.

Pseudoresistance means your depression appeared treatment-resistant, but the underlying reason wasn’t your brain’s biology. It was a correctable problem with treatment itself ^[1,2]. Estimates suggest pseudoresistance accounts for 30 to 60% of apparent non-response cases ^[1]. Before accepting a TRD diagnosis, your clinician should evaluate four things.

Was the diagnosis correct? Bipolar disorder frequently masquerades as unipolar depression. Patients who have failed multiple antidepressant trials have a higher likelihood of an underlying bipolar diathesis — a condition where antidepressants alone are not only ineffective, but can destabilize mood further ^[1]. This is especially critical for younger patients.

Were there hidden biological contributors? Untreated hypothyroidism, sleep apnea (which disrupts the sleep architecture critical to mood regulation), chronic inflammation, vitamin B12 deficiency, or testosterone deficiency in men can make depression biologically resistant to treatment. These get ruled out with a targeted medical workup, not assumed away ^[1].

Does your body process medication differently? This is where pharmacogenomics — genetic testing for how your body metabolizes drugs — becomes clinically important. Your liver enzymes, particularly CYP2D6 and CYP2C19, determine how fast you metabolize antidepressants. Ultrarapid metabolizers may clear a standard dose before it ever reaches therapeutic levels in the brain. Poor metabolizers may accumulate near-toxic levels at the same dose. Tenfold differences in drug exposure between individuals have been documented, yet most patients are prescribed a “standard dose” with no genetic testing whatsoever ^[1]. If you’ve failed multiple antidepressants, pharmacogenomic testing should be part of your evaluation.

Was there adequate psychotherapy? Many patients labeled as TRD have never received structured, evidence-based psychotherapy — specifically cognitive behavioral therapy — at the dose and frequency that research supports. A medication trial without adjunctive psychotherapy is, by some clinical definitions, an incomplete trial ^[1,2].

What a real TRD assessment looks like

At a specialty TRD clinic, or with a psychiatrist who works regularly with treatment-resistant cases, the evaluation should be comprehensive and methodical ^[1]. Expect your clinician to do five things.

1. Reconstruct your full medication history. Every antidepressant you’ve taken, the dose reached, the duration at that dose, why it was stopped, and the degree of symptom change. This is often done with validated instruments like the Antidepressant Treatment History Form (ATHF) or the Massachusetts General Hospital Staging Model (MGH-S).

2. Stage your level of treatment resistance. TRD exists on a spectrum, and staging matters for choosing the next treatment. A patient who has failed two SSRIs is clinically different from one who has failed two SSRIs, two SNRIs, an augmentation strategy, and a course of electroconvulsive therapy. Different stages unlock different evidence-based options ^[1].

3. Order targeted lab work. At minimum: thyroid function (TSH, free T4), complete blood count, comprehensive metabolic panel, vitamin B12, folate, fasting glucose, and inflammatory markers like C-reactive protein. Depending on the clinical picture: testosterone in men, cortisol, sleep study, or interleukin-6 ^[1].

4. Screen for comorbidities. Anxiety disorders, ADHD, PTSD, and substance use disorders frequently co-occur with depression — and if untreated, they can neutralize even the most effective antidepressant ^[1].

5. Assess severity with validated tools. The MADRS (Montgomery-Åsberg Depression Rating Scale) and the HAM-D (Hamilton Rating Scale for Depression) are the gold-standard instruments in TRD research. The PHQ-9 is widely used in outpatient settings. These tools provide an objective baseline so future treatment response can be tracked with precision rather than estimation ^[1].

The staging models: how psychiatrists measure “how resistant”

Clinicians use formal staging models to grade TRD severity. The most widely used is the Thase-Rush Staging Model ^[1].

More nuanced models, like the Maudsley Staging Method, also factor in episode duration and illness severity, generating a score from 3 to 15 that integrates chronicity into the clinical picture ^[1]. The MGH Staging Model goes further still, giving partial credit for partially optimized trials and augmentation strategies — the most granular staging available for clinical decision-making ^[1].

Why does staging matter to you? Because it directly determines which treatments you now qualify for, including FDA-approved therapies designed specifically for people who have failed standard antidepressants.

What happens after the diagnosis?

This part deserves to be said clearly, without hedging:

A TRD diagnosis does not mean nothing will work. It means standard treatments have not worked — and that is a categorically different statement.

The landscape of TRD treatment in 2026 is more advanced than at any prior point in psychiatric history. In January 2025, the FDA approved SPRAVATO® (esketamine nasal spray) as the first-ever monotherapy for adults with TRD — meaning it can now be used without a concurrent oral antidepressant ^[5]. SAINT (Stanford Accelerated Intelligent Neuromodulation Therapy), a 5-day, fMRI-guided transcranial magnetic stimulation protocol, demonstrated remission rates of approximately 90% in the original 2020 open-label trial and around 57% in the 2022 sham-controlled randomized trial ^[6,7]. A 2024 randomized trial directly comparing repetitive transcranial magnetic stimulation (rTMS) to a medication switch in moderate TRD found rTMS remission rates roughly five times higher than switching antidepressants ^[8]. Psilocybin-assisted therapy is producing some of the most striking trial data in recent psychiatric history ^[1].

These are not experimental fringe therapies. They are FDA-reviewed, peer-reviewed, replicable treatments — many of which your insurance may cover.

The diagnosis is not a wall. It’s a door. And on the other side of it are treatments that work specifically because standard antidepressants did not.

What this means if you’re reading this right now

If you’ve been on two or more antidepressants and still feel like yourself is out of reach — if you’re functioning, but barely; if you’ve been told the medication is “working” when you know it isn’t; if the fog never fully lifted even on a good medication day — this article was written for you.

What you’re experiencing has a name. It has a clinical framework. It has a biological explanation that has nothing to do with your effort, your attitude, or your willingness to get better.

And, most importantly, it has treatments.

The first step is an honest, thorough evaluation with a psychiatrist who specializes in treatment-resistant depression — not to add another antidepressant to the list, but to finally understand why the list got as long as it did, and what specifically your brain responds to instead.